Search Results - "Karp, D.D"

Drug development in the MD Anderson Cancer Center (MDACC) Clinical Translational Research Center (CTRC) – 2011–2015: The challenge of precision medicine in a very broad playing field by Dembla, V, Ray, D, Lockett, P, Fullmer, C, Subramanian, H, Subbiah, V, Fu, S, Janku, F, Tsimberidou, A.M, Naing, A, Piha-Paul, S.A, Hong, D.S, Pant, S, Miller, V.A, Lim, J, Le, H, Karp, D.D

“…Background: Phase 1 cancer drug development has been an extremely dynamic area in recent years. We have seen the arrival of multiple new classes of agents with…”
Get full text

169 BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform (Idylla™) by Janku, F, Huang, H.J, Claes, B, Falchook, G.S, Naing, A, Piha-Paul, S, Tsimberidou, A.M, Zinner, R.G, Karp, D.D, Fu, S, Subbiah, V, Hong, D.S, Wheler, J.J, Luthra, R.G, Patel, S.P, Kopetz, E.S, Sablon, E, Maertens, G, Kurzrock, R, Meric-Bernstam, F

Get full text

Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer by Janku, F., Johnson, L.K., Karp, D.D., Atkins, J.T., Singleton, P.A., Moss, J.

“…Methylnaltrexone (MNTX), a peripherally acting μ-opioid receptor (MOR) antagonist, is FDA-approved for treatment of opioid-induced constipation (OIC)…”
Get full text

1026MO Phase Ib dose escalation study of novel immunogenic cell death (ICD) inducer PT-112 plus PD-L1 inhibitor avelumab in solid tumours by Karp, D.D., Dronca, R.S., Camidge, R., Costello, B.A., Mansfield, A.S., Ames, T.D., Jimeno, J.M., Bryce, A.H.

Get full text

Phase II study of pembrolizumab for high-grade neuroendocrine tumors of the cervix and vulva by Frumovitz, M., Westin, S.N., Yap, T., Rodon, J.A., Karp, D.D., Abonofal, A., Jazaeri, A.A., Naing, A.

Get full text

1006 The anti-IGF-IR antibody figitumumab (CP-751,871) is active in patients with lung adenocarcinoma undergoing epithelial-tomesenchymal transition by Gualberto, A, Hixon, M.L, Dolled-Filhart, M.P, Chistensen, J, Rimm, D.L, Lee, A.V, Wang, Y.F, Pollak, M, Paz-Ares, L.G, Karp, D.D

Get full text

NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers by Yap, T.A., Ngoi, N., Dumbrava, E.E., Karp, D.D., Rodon Ahnert, J., Fu, S., Hong, D.S., Naing, A., Pant, S., Piha-Paul, S.A., Subbiah, V., Tsimberidou, A.M., Dufner, D., Rhudy, J., Gore, S., Ivy, S.P., Yuan, Y., Westin, S.N., Mills, G.B., Meric-Bernstam, F.

Get full text

73P Selinexor in combination with carboplatin and pemetrexed (CP) in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase Ib study by Thein, K.Z., Tsimberidou, A.M., Piha-Paul, S.A., Janku, F., Karp, D.D., Fu, S., Zarifa, A., Gong, J., Yap, T.A., Hong, D.S., Subbiah, V., Pant, S., Meric-Bernstam, F., Naing, A.

Get full text

72MO Selinexor in combination with standard chemotherapy in patients with advanced solid tumours: Results of an open label, single-center, multi-arm phase Ib study by Thein, K.Z., Tsimberidou, A.M., Piha-Paul, S.A., Janku, F., Karp, D.D., Fu, S., Zarifa, A., Gong, J., Hong, D.S., Yap, T.A., Subbiah, V., Pant, S., Meric-Bernstam, F., Naing, A.

Get full text

565P Selinexor in combination with topotecan in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm phase Ib study by Thein, K.Z., Tsimberidou, A.M., Piha-Paul, S., Janku, F., Karp, D.D., Fu, S., Zarifa, A., Gong, J., Hong, D.S., Yap, T.A., Subbiah, V., Pant, S., Meric-Bernstam, F., Naing, A.

Get full text

1124P Phase Ib study to evaluate the safety of selinexor (SEL) in combination with pembrolizumab (PEM) in patients with advanced malignancies- the: The melanoma experience by Glitza, I.C., Patel, S., Zarifa, A., Leung, C.H., Lin, H., McQuinn, L., Gong, J., Yilmaz, B., Chambers, J., Sulovic, S., John, I., Hennegan, T., Fu, S., Tsimberidou, A.M., Janku, F., Karp, D.D., Meric-Bernstam, F., Naing, A.

Get full text

554P Selinexor in combination with carboplatin and paclitaxel in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm phase Ib study by Thein, K.Z., Tsimberidou, A.M., Piha-Paul, S., Janku, F., Karp, D.D., Fu, S., Zarifa, A., Gong, J., Yap, T.A., Hong, D.S., Subbiah, V., Pant, S., Meric-Bernstam, F., Naing, A.

Get full text

DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial: Phase 1/2 Study of the ATR inhibitor (ATRi) berzosertib and PD-L1 inhibitor avelumab in patients (pts) with advanced solid tumors with DDR molecular alterations by Ngoi, N., Pilie, P.G., Piha-Paul, S.A., Dumbrava, E.E., Fu, S., Hong, D.S., Karp, D.D., Naing, A., Pant, S., Rodon Ahnert, J., Subbiah, V., Tsimberidou, A.M., Salguero, C., Brown, C.V., Hoadley, W.E., Johnson, A., Yuan, Y., Westin, S.N., Meric-Bernstam, F., Yap, T.A.

Get full text

779P Validation of prognostic scores in patients with metastatic bladder carcinoma (mBC) enrolled in early phase clinical trials by Alhalabi, O., Hahn, A.W., Msaouel, P., Meric-Bernstam, F., Naing, A., Piha-Paul, S., Janku, F., Pant, S., Yap, T.A., Hong, D.S., Fu, S., Karp, D.D., Campbell, E., Campbell, M.T., Shah, A.Y., Tannir, N., Siefker-Radtke, A.O., Gao, J., Roszik, J., Subbiah, V.

Get full text

Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer by Janku, F., Johnson, L.K., Karp, D.D., Atkins, J.T., Singleton, P.A., Moss, J.

Get full text

PT-112: A well-tolerated novel immunogenic cell death (ICD) inducer with activity in advanced solid tumors by Karp, D D, Camidge, D R, Infante, J R, Ames, T D, Jimeno, J M, Bryce, A H

Get full text

423 - Drug development in the MD Anderson Cancer Center (MDACC) Clinical Translational Research Center (CTRC) – 2011–2015: The challenge of precision medicine in a very broad playing field by Dembla, V., Ray, D., Lockett, P., Fullmer, C., Subramanian, H., Subbiah, V., Fu, S., Janku, F., Tsimberidou, A.M., Naing, A., Piha-Paul, S.A., Hong, D.S., Pant, S., Miller, V.A., Lim, J., Le, H., Karp, D.D.

Get full text

MultiplexKRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction by Janku, F., Huang, H.J., Fujii, T., Shelton, D.N., Madwani, K., Fu, S., Tsimberidou, A.M., Piha-Paul, S.A., Wheler, J.J., Zinner, R.G., Naing, A., Hong, D.S., Karp, D.D., Cabrilo, G., Kopetz, E.S., Subbiah, V., Luthra, R., Kee, B.K., Eng, C., Morris, V.K., Karlin-Neumann, G.A., Meric-Bernstam, F.

“…Cell-free DNA (cfDNA) from plasma offers easily obtainable material forKRAS mutation analysis. Novel, multiplex, and accurate diagnostic systems using small…”
Get full text

PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers by Dumbrava, E.E., Call, S.G., Huang, H.J., Stuckett, A.L., Madwani, K., Adat, A., Hong, D.S., Piha-Paul, S.A., Subbiah, V., Karp, D.D., Fu, S., Naing, A., Tsimberidou, A.M., Moulder, S.L., Koenig, K.H., Barcenas, C.H., Kee, B.K., Fogelman, D.R., Kopetz, E.S., Meric-Bernstam, F., Janku, F.

“…Oncogenic mutations in PIK3CA are prevalent in diverse cancers and can be targeted with inhibitors of the phosphoinositide-3-kinase/protein kinase B/mammalian…”
Get full text

A phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumors by Karp, D.D, Ferrante, K.J, Tensfeldt, T.G, Thurer, R.L, LoCicero, J, Huberman, M.S, Wirth, F, Hellman, R, Poulin, P, Silberman, S.L, Redifer, P, Allen, L.F, Posner, M, Schnipper, L.E

Get full text